# Dabigatran for Mitral Stenosis Atrial Fibrillation

Study · id `cardio:ct-nct04045093` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04045093](<https://clinicaltrials.gov/study/NCT04045093>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04045093

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 370 participants.

## Technical summary

Registry record NCT04045093. Randomized; no masking; primary purpose prevention. Start 2020-10-22 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 370 participants (planned count; ClinicalTrials.gov record NCT04045093, source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)
- Started: 2020-10-22 (actual) (ClinicalTrials.gov record NCT04045093, source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)
- Primary completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT04045093, source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT04045093, source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT04045093, source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04045093-2025-12-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dabigatran for Mitral Stenosis Atrial Fibrillation
- Acronym: David-MS
- Condition: Atrial Fibrillation
- Condition: Mitral Stenosis
- Intervention (Drug): Dabigatran etexilate
- Intervention (Drug): Warfarin
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral stenosis (`cardio:mitral-stenosis`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: abf80748986e6a829f3d532e370a51f2a481b814b34fc7633658d8542d02f97a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
